MediWound planning BLA for thermal burn agent

MediWound Ltd. (NASDAQ:MDWD) said NexoBrid met the primary endpoint of a greater incidence of complete eschar removal vs. gel vehicle (93.3% vs. 4%, p<0.0001) in the Phase III DETECT trial in 175 patients with deep partial or full-thickness thermal burns. The company plans to submit a BLA to FDA next half for NexoBrid...